MedTrace Logo

Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies

NCT02209740 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 245

Last updated 2015-12-30

No results posted yet for this study

Summary

Renal outcome could be different after switching tenofovir to different antiretroviral strategies, in case of renal toxicity. Therefore, it is necessary to evaluate the importance of renal evolution in these patients, in terms of grade and time to renal improvement, according to the different options after interrupting tenofovir. The aim of this study was to explore the renal outcome after tenofovir according to new antiretroviral regimen.

Conditions

  • Renal Disease

Interventions

OTHER

Tenofovir switch

Patients switched tenofovir to different antiretroviral regimen according to physicians decision

Sponsors & Collaborators

  • Asociacion para el Estudio de las Enfermedades Infecciosas

    lead NETWORK

Principal Investigators

  • Jose L Casado, MD · Asociacion para el Estudio de las Enfermedades Infecciosas

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02209740 on ClinicalTrials.gov